Gyrodyne, LLC (GYRO)
NASDAQ: GYRO · Real-Time Price · USD
9.36
-0.35 (-3.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Gyrodyne, LLC owns and manages a diversified portfolio of real estate properties comprising office, industrial and service-oriented properties in the New York metropolitan area.
Gyrodyne owns a 63 acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property which is the subject of plans to seek value-enhancing entitlements.
Gyrodyne also owns a medical office park in Cortlandt Manor, New York which is also the subject of a subdivision application.
Gyrodyne's common shares are traded on the NASDAQ Stock Market under the symbol GYRO.
Gyrodyne, LLC
Country | United States |
Founded | 1946 |
Industry | Real Estate Services |
Sector | Real Estate |
Employees | 6 |
CEO | Gary Fitlin |
Contact Details
Address: One Flowerfield, Suite 24 Saint James, New York 11780-1503 United States | |
Phone | (631) 584-5400 |
Website | gyrodyne.com |
Stock Details
Ticker Symbol | GYRO |
Exchange | NASDAQ |
Fiscal Year | September - August |
Reporting Currency | USD |
CIK Code | 0001589061 |
CUSIP Number | 403829104 |
ISIN Number | US4038291047 |
Employer ID | 46-3838291 |
SIC Code | 6512 |
Key Executives
Name | Position |
---|---|
Gary Jay Fitlin | President, Chief Executive Officer, Chief Financial Officer and Treasurer |
Peter Pitsiokos | Chief Compliance Officer, Chief Operating Officer, Executive Vice President and Corporate Secretary |
Dawn Ibraham | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 19, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 16, 2024 | 8-K | Current Report |
Oct 11, 2024 | 8-K | Current Report |
Oct 7, 2024 | 8-K | Current Report |
Sep 9, 2024 | DEF 14A | Other definitive proxy statements |
Aug 9, 2024 | 10-Q | Quarterly Report |
May 10, 2024 | 10-Q | Quarterly Report |
Mar 29, 2024 | 10-K | Annual Report |